Pretomanid: A Breakthrough Nitroimidazole for Drug-Resistant Tuberculosis

　　Pretomanid belongs to the nitroimidazole class of anti-tuberculosis drugs.Its unique mechanism involves activation by bacterial nitroreductase under anaerobic conditions(e.g.,caseous necrotic foci),producing reactive metabolites that kill non-replicating(dormant)tubercle bacilli—a state that conventional drugs cannot effectively target.This gives pretomanid potent activity against both drug-resistant strains and persistent bacterial populations.

　　Core Role in Drug-Resistant TB Treatment

　　In 2019,the U.S.FDA approved pretomanid as part of the BPaL regimen(bedaquiline+pretomanid+linezolid)for treating extensively drug-resistant tuberculosis(XDR-TB)and multidrug-resistant tuberculosis(MDR-TB)that is rifampicin-resistant or intolerant to isoniazid.This was the first new structural class of anti-TB drug approved in nearly 40 years.The BPaL regimen is fully oral,lasts only 6–9 months(compared to 18–24 months for conventional therapy),and eliminates injectable agents,greatly improving patient adherence.

　　Clinical Efficacy:Nix-TB Trial

　　The pivotal phase III Nix-TB study enrolled 109 patients with XDR-TB or treatment-intolerant MDR-TB,who received BPaL for six months.The primary endpoint was bacteriological failure or relapse at six months post-treatment.Results showed 87.1%(95 patients)achieved a favorable outcome,with most converting sputum culture by month six.The regimen raised treatment success rates from~30–40%with conventional therapy to nearly 90%,with a relapse rate below 5%.Based on these data,the World Health Organization now recommends BPaL as the preferred regimen for XDR-TB.

　　Advantages:Shorter Duration and Better Adherence

　　Traditional XDR-TB treatment requires multiple second-line drugs,including daily injectable aminoglycosides with significant nephrotoxicity and ototoxicity,and extends for 18–24 months,leading to poor compliance.The all-oral BPaL regimen reduces therapy to 6–9 months,substantially easing patient burden.Moreover,pretomanid has a high genetic barrier to resistance;no primary resistance was observed in early studies.

　　Critical Combination Therapy

　　Pretomanid must always be used in combination with bedaquiline and linezolid;monotherapy is contraindicated.The three drugs act synergistically:bedaquiline inhibits ATP synthase,pretomanid targets anaerobic bacteria,and linezolid blocks protein synthesis.Together they cover bacteria in different metabolic states and prevent emergence of resistance.Co-administration with delamanid is not recommended due to similar mechanisms and lack of added benefit,with potential for additive toxicity.

　　Safety and Side Effects

　　The most common adverse events include nausea(~40%),headache(~30%),and vomiting(~20%),mostly grade 1–2 and manageable with supportive care.Serious concerns include hepatotoxicity(ALT/AST>5×ULN in~5%),necessitating monthly liver function monitoring;myelosuppression is primarily attributed to linezolid rather than pretomanid itself.Importantly,pretomanid does not prolong the QTc interval,eliminating cardiac toxicity risk associated with bedaquiline.

　　Revolutionizing TB Treatment Strategy

　　The success of pretomanid validates the strategy of targeting dormant bacterial populations.Conventional drugs kill only actively replicating organisms,requiring prolonged therapy to allow dormant bacteria to become active and then be eliminated.Pretomanid directly kills dormant cells,making short-course therapy feasible.This paradigm shift holds promise for developing future anti-infective agents.